- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07271017
Robotassisterad prostatabiopsi med en ny ultraljudssond
Robotassisterad prostata biopsi med en ny ultraljudsprobe
Prostate cancer (PCa) is the most diagnosed type of cancer and the second leading cause of cancer related deaths among US men, and its incidence has increased steadily in the last decade. Efforts to address the rise in PCa diagnosis without overdetection and overtreatment include targeted biopsy techniques for clinically significant PCa using magnetic resonance imaging (MRI), and precision targeted biopsy guided by ultrasound and fused to the MRI.
The study aims to improve prostate biopsy with a novel ultrasound probe and robot developed at Johns Hopkins, the ProBot device. The trial is a Phase 1 clinical trial to evaluate the safety and feasibility of the new device.
ProBot is an entirely new concept including a novel ultrasound probe and robot kinematics specifically designed for the prostate. It operates with only two degrees of freedom configured such that the motions for 3D image scanning and biopsy may not deform the prostate gland, thus improving the accuracy of MRI-ultrasound fusion and needle targeting at biopsy.
ProBot is a small and lightweight robot (1.3Kg including the ultrasound probe). It allows hands-free operation of its ultrasound probe at 3D image scanning and needle targeting supervised by the urologist.
In addition to MRI-targeted biopsy (TB), at systematic biopsy (SB), instead of using the common template plan that is the same for all patients, the innovative software optimizes the plan for each patient to obtain a diagnosis that is representative of the whole gland histology. The ProBot robot is also uniquely capable of transrectal (TR) and transperineal (TP) biopsy.
The aims of the study are to determine the safety and feasibility of the new device at TR and TP biopsies.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Rana Harb
- Telefonnummer: 410-502-5500
- E-post: rharb1@jhmi.edu
Studera Kontakt Backup
- Namn: Sara A Naizghi
- Telefonnummer: 720-965-9494 4105501980
- E-post: snaizgh1@jh.edu
Studieorter
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Rekrytering
- Johns Hopkins Hospital
-
Kontakt:
- Rana Harb
- Telefonnummer: 410-502-5500
- E-post: rharb1@jhmi.edu
-
Kontakt:
- Sara A Naizghi
- Telefonnummer: 720-965-9494
- E-post: snaizgh1@jh.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Included in the study will be:
-
Men between the ages of 40 and 75
-
Men must have one of the following "high risk" features:
- PSA > 4.0 ng/ml and/or abnormal digital rectal examination (DRE)
- ASAP (atypical small acinar proliferation) on previous biopsy
-
Men with mpMRI or bpMRI exams, including both PI-RADS ≤2 and PI-RADS ≥3.
Excluded from the study will be patients without available mpMRI exams and patients:
-
Females and children because of the prostate cancer targeted disease.
-
Patients who are not recommended or in whom TR or TP prostate biopsy is considered high-risk:
- Patients with previous rectal surgery.
- Patients with anal stenosis or coagulopathy.
- Patients on active anticoagulation medication (eg. Coumadin, Lovenox, or Heparin).
- Patients who cannot tolerate periprostatic Lidocaine block anesthesia or in whom anesthesia is considered high-risk.
-
Patients who already had a prostate biopsy taken with the ProBot investigational device.
-
Vulnerable populations, such as prisoners, institutionalized individuals.
-
Patients who are unwilling or unable to sign informed consent (no assent required).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Enhetens genomförbarhet
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Transrectal biopsy (TR)
Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transrectal path |
Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot |
|
Experimentell: Transperineal biopsy (TP)
Biopsy guided by transrectal ultrasound fused with MRI and needle inserted on a transperineal path. |
Precision personalized prostate biopsy with a novel ultrasound probe and robot, ProBot |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Device feasibility as assessed by patient discomfort score
Tidsram: Immediately after the procedure
|
Scale 1-10, 10 highest discomfort |
Immediately after the procedure
|
|
Device feasibility as assessed by maximal procedural pain
Tidsram: Immediately after the procedure
|
Scale 1-10, 10 highest pain |
Immediately after the procedure
|
|
Device feasibility as assessed by the rate of complications
Tidsram: Throughout the study, each case recorded within 1 month of the procedure
|
Rate of complications |
Throughout the study, each case recorded within 1 month of the procedure
|
|
Device feasibility as assessed by serious adverse events
Tidsram: Up to 1 month post procedure
|
Serious Adverse events throughout the study |
Up to 1 month post procedure
|
|
Device feasibility as assessed by the rate of successful completion of cases
Tidsram: Immediately post procedure
|
Rate of cases completed successfully throughout the study |
Immediately post procedure
|
|
Device feasibility as assessed by the procedure time
Tidsram: Immediately post procedure
|
Times of the procedures measured in minutes throughout the study |
Immediately post procedure
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Prostate cancer detection rates at targeted biopsy (TB)
Tidsram: Up to 1 month post procedure
|
Clinically significant PCa detection rates at TB throughout the study |
Up to 1 month post procedure
|
|
Prostate cancer detection rates at systematic biopsy (SB)
Tidsram: Up to one month post procedure
|
Clinically significant PCa detection rates at SB throughout the study |
Up to one month post procedure
|
|
Needle targeting errors
Tidsram: Immediately post procedure
|
Measured in ultrasound throughout the study |
Immediately post procedure
|
|
Prostate deformations (mm)
Tidsram: Immediately post procedure
|
Maximum deformation of the gland between the start and end of the procedure measured in [mm] throughout the study |
Immediately post procedure
|
|
Prostate displacement (mm)
Tidsram: Immediately post procedure
|
Displacement of the gland between the start and end of the procedure measured in [mm] throughout the study |
Immediately post procedure
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Misop Han, MD, Johns Hopkins University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IRB00229568
- R01CA303859 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .